nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—Oxycodone—Galantamine—Alzheimer's disease	0.269	0.363	CrCrCtD
Naltrexone—Morphine—Galantamine—Alzheimer's disease	0.251	0.338	CrCrCtD
Naltrexone—Hydrocodone—Galantamine—Alzheimer's disease	0.222	0.299	CrCrCtD
Naltrexone—OPRM1—telencephalic ventricle—Alzheimer's disease	0.00549	0.208	CbGeAlD
Naltrexone—OPRD1—forebrain—Alzheimer's disease	0.0021	0.0796	CbGeAlD
Naltrexone—OPRK1—forebrain—Alzheimer's disease	0.00202	0.0763	CbGeAlD
Naltrexone—OPRD1—telencephalon—Alzheimer's disease	0.00193	0.0732	CbGeAlD
Naltrexone—Naloxone—CREB1—Alzheimer's disease	0.00175	0.429	CrCbGaD
Naltrexone—OPRM1—forebrain—Alzheimer's disease	0.00143	0.0543	CbGeAlD
Naltrexone—OPRM1—telencephalon—Alzheimer's disease	0.00132	0.0499	CbGeAlD
Naltrexone—OPRD1—nervous system—Alzheimer's disease	0.00114	0.0432	CbGeAlD
Naltrexone—OPRD1—central nervous system—Alzheimer's disease	0.0011	0.0416	CbGeAlD
Naltrexone—OPRK1—nervous system—Alzheimer's disease	0.00109	0.0414	CbGeAlD
Naltrexone—OPRK1—central nervous system—Alzheimer's disease	0.00105	0.0399	CbGeAlD
Naltrexone—OPRK1—cerebellum—Alzheimer's disease	0.00103	0.039	CbGeAlD
Naltrexone—OPRD1—brain—Alzheimer's disease	0.000873	0.033	CbGeAlD
Naltrexone—OPRK1—brain—Alzheimer's disease	0.000837	0.0317	CbGeAlD
Naltrexone—ABCB1—blood vessel—Alzheimer's disease	0.000784	0.0297	CbGeAlD
Naltrexone—OPRM1—nervous system—Alzheimer's disease	0.000779	0.0295	CbGeAlD
Naltrexone—OPRM1—central nervous system—Alzheimer's disease	0.00075	0.0284	CbGeAlD
Naltrexone—OPRM1—brain—Alzheimer's disease	0.000595	0.0225	CbGeAlD
Naltrexone—ABCB1—embryo—Alzheimer's disease	0.000468	0.0177	CbGeAlD
Naltrexone—ABCB1—forebrain—Alzheimer's disease	0.000414	0.0157	CbGeAlD
Naltrexone—ABCB1—telencephalon—Alzheimer's disease	0.000381	0.0144	CbGeAlD
Naltrexone—Methylnaltrexone—CYP2D6—Alzheimer's disease	0.000372	0.0913	CrCbGaD
Naltrexone—Naloxone—ESR1—Alzheimer's disease	0.00034	0.0835	CrCbGaD
Naltrexone—Hydromorphone—PTGS1—Alzheimer's disease	0.000295	0.0725	CrCbGaD
Naltrexone—Conjunctivitis—Memantine—Alzheimer's disease	0.000293	0.00151	CcSEcCtD
Naltrexone—Urinary tract infection—Memantine—Alzheimer's disease	0.000293	0.00151	CcSEcCtD
Naltrexone—Cough—Galantamine—Alzheimer's disease	0.000292	0.00151	CcSEcCtD
Naltrexone—Acute coronary syndrome—Rivastigmine—Alzheimer's disease	0.000291	0.0015	CcSEcCtD
Naltrexone—Convulsion—Galantamine—Alzheimer's disease	0.00029	0.0015	CcSEcCtD
Naltrexone—Myocardial infarction—Rivastigmine—Alzheimer's disease	0.000289	0.00149	CcSEcCtD
Naltrexone—Hypertension—Galantamine—Alzheimer's disease	0.000289	0.00149	CcSEcCtD
Naltrexone—Urinary tract infection—Rivastigmine—Alzheimer's disease	0.000287	0.00148	CcSEcCtD
Naltrexone—Conjunctivitis—Rivastigmine—Alzheimer's disease	0.000287	0.00148	CcSEcCtD
Naltrexone—Hepatobiliary disease—Memantine—Alzheimer's disease	0.000285	0.00147	CcSEcCtD
Naltrexone—Myalgia—Galantamine—Alzheimer's disease	0.000285	0.00147	CcSEcCtD
Naltrexone—Arthralgia—Galantamine—Alzheimer's disease	0.000285	0.00147	CcSEcCtD
Naltrexone—Chest pain—Galantamine—Alzheimer's disease	0.000285	0.00147	CcSEcCtD
Naltrexone—Epistaxis—Memantine—Alzheimer's disease	0.000284	0.00147	CcSEcCtD
Naltrexone—Anxiety—Galantamine—Alzheimer's disease	0.000284	0.00147	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Galantamine—Alzheimer's disease	0.000283	0.00146	CcSEcCtD
Naltrexone—Sinusitis—Memantine—Alzheimer's disease	0.000283	0.00146	CcSEcCtD
Naltrexone—Discomfort—Galantamine—Alzheimer's disease	0.000281	0.00145	CcSEcCtD
Naltrexone—Hepatobiliary disease—Rivastigmine—Alzheimer's disease	0.000279	0.00144	CcSEcCtD
Naltrexone—Dry mouth—Galantamine—Alzheimer's disease	0.000279	0.00144	CcSEcCtD
Naltrexone—Epistaxis—Rivastigmine—Alzheimer's disease	0.000278	0.00144	CcSEcCtD
Naltrexone—Tinnitus—Donepezil—Alzheimer's disease	0.000278	0.00143	CcSEcCtD
Naltrexone—Oxymorphone—CYP2D6—Alzheimer's disease	0.000278	0.0681	CrCbGaD
Naltrexone—Sinusitis—Rivastigmine—Alzheimer's disease	0.000277	0.00143	CcSEcCtD
Naltrexone—Confusional state—Galantamine—Alzheimer's disease	0.000275	0.00142	CcSEcCtD
Naltrexone—Hepatitis—Memantine—Alzheimer's disease	0.00027	0.0014	CcSEcCtD
Naltrexone—Hallucination—Memantine—Alzheimer's disease	0.000269	0.00139	CcSEcCtD
Naltrexone—Shock—Galantamine—Alzheimer's disease	0.000269	0.00139	CcSEcCtD
Naltrexone—Pharyngitis—Memantine—Alzheimer's disease	0.000268	0.00139	CcSEcCtD
Naltrexone—Nervous system disorder—Galantamine—Alzheimer's disease	0.000268	0.00138	CcSEcCtD
Naltrexone—Chills—Donepezil—Alzheimer's disease	0.000267	0.00138	CcSEcCtD
Naltrexone—Tachycardia—Galantamine—Alzheimer's disease	0.000267	0.00138	CcSEcCtD
Naltrexone—Connective tissue disorder—Memantine—Alzheimer's disease	0.000266	0.00137	CcSEcCtD
Naltrexone—Skin disorder—Galantamine—Alzheimer's disease	0.000265	0.00137	CcSEcCtD
Naltrexone—Hepatitis—Rivastigmine—Alzheimer's disease	0.000265	0.00137	CcSEcCtD
Naltrexone—Hyperhidrosis—Galantamine—Alzheimer's disease	0.000264	0.00136	CcSEcCtD
Naltrexone—Hallucination—Rivastigmine—Alzheimer's disease	0.000263	0.00136	CcSEcCtD
Naltrexone—Alopecia—Donepezil—Alzheimer's disease	0.000263	0.00136	CcSEcCtD
Naltrexone—Pharyngitis—Rivastigmine—Alzheimer's disease	0.000263	0.00136	CcSEcCtD
Naltrexone—Mental disorder—Donepezil—Alzheimer's disease	0.000261	0.00135	CcSEcCtD
Naltrexone—Anorexia—Galantamine—Alzheimer's disease	0.00026	0.00134	CcSEcCtD
Naltrexone—Connective tissue disorder—Rivastigmine—Alzheimer's disease	0.00026	0.00134	CcSEcCtD
Naltrexone—Malnutrition—Donepezil—Alzheimer's disease	0.000259	0.00134	CcSEcCtD
Naltrexone—Flatulence—Donepezil—Alzheimer's disease	0.000256	0.00132	CcSEcCtD
Naltrexone—Tension—Donepezil—Alzheimer's disease	0.000254	0.00131	CcSEcCtD
Naltrexone—Dysgeusia—Donepezil—Alzheimer's disease	0.000254	0.00131	CcSEcCtD
Naltrexone—Eye disorder—Memantine—Alzheimer's disease	0.000253	0.00131	CcSEcCtD
Naltrexone—Tinnitus—Memantine—Alzheimer's disease	0.000252	0.0013	CcSEcCtD
Naltrexone—Nervousness—Donepezil—Alzheimer's disease	0.000252	0.0013	CcSEcCtD
Naltrexone—Cardiac disorder—Memantine—Alzheimer's disease	0.000251	0.0013	CcSEcCtD
Naltrexone—Back pain—Donepezil—Alzheimer's disease	0.000251	0.0013	CcSEcCtD
Naltrexone—Muscle spasms—Donepezil—Alzheimer's disease	0.000249	0.00129	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.000249	0.00129	CcSEcCtD
Naltrexone—Eye disorder—Rivastigmine—Alzheimer's disease	0.000247	0.00128	CcSEcCtD
Naltrexone—Insomnia—Galantamine—Alzheimer's disease	0.000247	0.00128	CcSEcCtD
Naltrexone—Tinnitus—Rivastigmine—Alzheimer's disease	0.000247	0.00127	CcSEcCtD
Naltrexone—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.000246	0.00127	CcSEcCtD
Naltrexone—Angiopathy—Memantine—Alzheimer's disease	0.000245	0.00127	CcSEcCtD
Naltrexone—Paraesthesia—Galantamine—Alzheimer's disease	0.000245	0.00127	CcSEcCtD
Naltrexone—Vision blurred—Donepezil—Alzheimer's disease	0.000244	0.00126	CcSEcCtD
Naltrexone—Immune system disorder—Memantine—Alzheimer's disease	0.000244	0.00126	CcSEcCtD
Naltrexone—Mediastinal disorder—Memantine—Alzheimer's disease	0.000244	0.00126	CcSEcCtD
Naltrexone—Tremor—Donepezil—Alzheimer's disease	0.000243	0.00126	CcSEcCtD
Naltrexone—Somnolence—Galantamine—Alzheimer's disease	0.000243	0.00125	CcSEcCtD
Naltrexone—Chills—Memantine—Alzheimer's disease	0.000243	0.00125	CcSEcCtD
Naltrexone—Hydrocodone—CYP2D6—Alzheimer's disease	0.000243	0.0595	CrCbGaD
Naltrexone—Ill-defined disorder—Donepezil—Alzheimer's disease	0.000241	0.00124	CcSEcCtD
Naltrexone—Angiopathy—Rivastigmine—Alzheimer's disease	0.00024	0.00124	CcSEcCtD
Naltrexone—Alopecia—Memantine—Alzheimer's disease	0.000239	0.00123	CcSEcCtD
Naltrexone—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.000238	0.00123	CcSEcCtD
Naltrexone—Agitation—Donepezil—Alzheimer's disease	0.000238	0.00123	CcSEcCtD
Naltrexone—Chills—Rivastigmine—Alzheimer's disease	0.000237	0.00123	CcSEcCtD
Naltrexone—Decreased appetite—Galantamine—Alzheimer's disease	0.000237	0.00123	CcSEcCtD
Naltrexone—Mental disorder—Memantine—Alzheimer's disease	0.000237	0.00122	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.000236	0.00122	CcSEcCtD
Naltrexone—Malnutrition—Memantine—Alzheimer's disease	0.000235	0.00122	CcSEcCtD
Naltrexone—Fatigue—Galantamine—Alzheimer's disease	0.000235	0.00122	CcSEcCtD
Naltrexone—Malaise—Donepezil—Alzheimer's disease	0.000234	0.00121	CcSEcCtD
Naltrexone—Alopecia—Rivastigmine—Alzheimer's disease	0.000234	0.00121	CcSEcCtD
Naltrexone—Constipation—Galantamine—Alzheimer's disease	0.000234	0.00121	CcSEcCtD
Naltrexone—Syncope—Donepezil—Alzheimer's disease	0.000233	0.0012	CcSEcCtD
Naltrexone—Flatulence—Memantine—Alzheimer's disease	0.000232	0.0012	CcSEcCtD
Naltrexone—Mental disorder—Rivastigmine—Alzheimer's disease	0.000232	0.0012	CcSEcCtD
Naltrexone—Tension—Memantine—Alzheimer's disease	0.000231	0.00119	CcSEcCtD
Naltrexone—Dysgeusia—Memantine—Alzheimer's disease	0.000231	0.00119	CcSEcCtD
Naltrexone—Malnutrition—Rivastigmine—Alzheimer's disease	0.00023	0.00119	CcSEcCtD
Naltrexone—Nervousness—Memantine—Alzheimer's disease	0.000229	0.00118	CcSEcCtD
Naltrexone—Loss of consciousness—Donepezil—Alzheimer's disease	0.000228	0.00118	CcSEcCtD
Naltrexone—Back pain—Memantine—Alzheimer's disease	0.000228	0.00118	CcSEcCtD
Naltrexone—Flatulence—Rivastigmine—Alzheimer's disease	0.000227	0.00117	CcSEcCtD
Naltrexone—Cough—Donepezil—Alzheimer's disease	0.000226	0.00117	CcSEcCtD
Naltrexone—Tension—Rivastigmine—Alzheimer's disease	0.000226	0.00117	CcSEcCtD
Naltrexone—Dysgeusia—Rivastigmine—Alzheimer's disease	0.000226	0.00117	CcSEcCtD
Naltrexone—Feeling abnormal—Galantamine—Alzheimer's disease	0.000225	0.00116	CcSEcCtD
Naltrexone—Convulsion—Donepezil—Alzheimer's disease	0.000225	0.00116	CcSEcCtD
Naltrexone—ABCB1—nervous system—Alzheimer's disease	0.000225	0.0085	CbGeAlD
Naltrexone—Hypertension—Donepezil—Alzheimer's disease	0.000224	0.00116	CcSEcCtD
Naltrexone—Nervousness—Rivastigmine—Alzheimer's disease	0.000224	0.00116	CcSEcCtD
Naltrexone—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.000223	0.00115	CcSEcCtD
Naltrexone—Back pain—Rivastigmine—Alzheimer's disease	0.000223	0.00115	CcSEcCtD
Naltrexone—Vision blurred—Memantine—Alzheimer's disease	0.000222	0.00115	CcSEcCtD
Naltrexone—Muscle spasms—Rivastigmine—Alzheimer's disease	0.000221	0.00114	CcSEcCtD
Naltrexone—Oxycodone—CYP2D6—Alzheimer's disease	0.000221	0.0543	CrCbGaD
Naltrexone—Chest pain—Donepezil—Alzheimer's disease	0.000221	0.00114	CcSEcCtD
Naltrexone—Myalgia—Donepezil—Alzheimer's disease	0.000221	0.00114	CcSEcCtD
Naltrexone—Arthralgia—Donepezil—Alzheimer's disease	0.000221	0.00114	CcSEcCtD
Naltrexone—Tremor—Memantine—Alzheimer's disease	0.000221	0.00114	CcSEcCtD
Naltrexone—Anxiety—Donepezil—Alzheimer's disease	0.00022	0.00114	CcSEcCtD
Naltrexone—Ill-defined disorder—Memantine—Alzheimer's disease	0.000218	0.00113	CcSEcCtD
Naltrexone—Discomfort—Donepezil—Alzheimer's disease	0.000218	0.00113	CcSEcCtD
Naltrexone—Vision blurred—Rivastigmine—Alzheimer's disease	0.000217	0.00112	CcSEcCtD
Naltrexone—Agitation—Memantine—Alzheimer's disease	0.000216	0.00112	CcSEcCtD
Naltrexone—ABCB1—central nervous system—Alzheimer's disease	0.000216	0.00818	CbGeAlD
Naltrexone—Dry mouth—Donepezil—Alzheimer's disease	0.000216	0.00112	CcSEcCtD
Naltrexone—Abdominal pain—Galantamine—Alzheimer's disease	0.000216	0.00112	CcSEcCtD
Naltrexone—Body temperature increased—Galantamine—Alzheimer's disease	0.000216	0.00112	CcSEcCtD
Naltrexone—Tremor—Rivastigmine—Alzheimer's disease	0.000216	0.00111	CcSEcCtD
Naltrexone—Ill-defined disorder—Rivastigmine—Alzheimer's disease	0.000214	0.0011	CcSEcCtD
Naltrexone—Confusional state—Donepezil—Alzheimer's disease	0.000213	0.0011	CcSEcCtD
Naltrexone—Malaise—Memantine—Alzheimer's disease	0.000212	0.0011	CcSEcCtD
Naltrexone—Agitation—Rivastigmine—Alzheimer's disease	0.000212	0.00109	CcSEcCtD
Naltrexone—Oedema—Donepezil—Alzheimer's disease	0.000212	0.00109	CcSEcCtD
Naltrexone—ABCB1—cerebellum—Alzheimer's disease	0.000211	0.008	CbGeAlD
Naltrexone—Syncope—Memantine—Alzheimer's disease	0.000211	0.00109	CcSEcCtD
Naltrexone—Infection—Donepezil—Alzheimer's disease	0.00021	0.00109	CcSEcCtD
Naltrexone—Shock—Donepezil—Alzheimer's disease	0.000208	0.00108	CcSEcCtD
Naltrexone—Palpitations—Memantine—Alzheimer's disease	0.000208	0.00107	CcSEcCtD
Naltrexone—Malaise—Rivastigmine—Alzheimer's disease	0.000208	0.00107	CcSEcCtD
Naltrexone—Nervous system disorder—Donepezil—Alzheimer's disease	0.000208	0.00107	CcSEcCtD
Naltrexone—Loss of consciousness—Memantine—Alzheimer's disease	0.000207	0.00107	CcSEcCtD
Naltrexone—Syncope—Rivastigmine—Alzheimer's disease	0.000207	0.00107	CcSEcCtD
Naltrexone—Cough—Memantine—Alzheimer's disease	0.000205	0.00106	CcSEcCtD
Naltrexone—Hyperhidrosis—Donepezil—Alzheimer's disease	0.000205	0.00106	CcSEcCtD
Naltrexone—Convulsion—Memantine—Alzheimer's disease	0.000204	0.00105	CcSEcCtD
Naltrexone—Buprenorphine—CYP2D6—Alzheimer's disease	0.000204	0.05	CrCbGaD
Naltrexone—Palpitations—Rivastigmine—Alzheimer's disease	0.000204	0.00105	CcSEcCtD
Naltrexone—Hypertension—Memantine—Alzheimer's disease	0.000203	0.00105	CcSEcCtD
Naltrexone—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.000202	0.00105	CcSEcCtD
Naltrexone—Anorexia—Donepezil—Alzheimer's disease	0.000202	0.00104	CcSEcCtD
Naltrexone—Hypersensitivity—Galantamine—Alzheimer's disease	0.000201	0.00104	CcSEcCtD
Naltrexone—Hydromorphone—CYP2D6—Alzheimer's disease	0.000201	0.0493	CrCbGaD
Naltrexone—Cough—Rivastigmine—Alzheimer's disease	0.000201	0.00104	CcSEcCtD
Naltrexone—Arthralgia—Memantine—Alzheimer's disease	0.0002	0.00104	CcSEcCtD
Naltrexone—Myalgia—Memantine—Alzheimer's disease	0.0002	0.00104	CcSEcCtD
Naltrexone—Chest pain—Memantine—Alzheimer's disease	0.0002	0.00104	CcSEcCtD
Naltrexone—Anxiety—Memantine—Alzheimer's disease	0.0002	0.00103	CcSEcCtD
Naltrexone—Convulsion—Rivastigmine—Alzheimer's disease	0.0002	0.00103	CcSEcCtD
Naltrexone—Hypertension—Rivastigmine—Alzheimer's disease	0.000199	0.00103	CcSEcCtD
Naltrexone—Discomfort—Memantine—Alzheimer's disease	0.000198	0.00102	CcSEcCtD
Naltrexone—Myalgia—Rivastigmine—Alzheimer's disease	0.000196	0.00101	CcSEcCtD
Naltrexone—Chest pain—Rivastigmine—Alzheimer's disease	0.000196	0.00101	CcSEcCtD
Naltrexone—Arthralgia—Rivastigmine—Alzheimer's disease	0.000196	0.00101	CcSEcCtD
Naltrexone—Dry mouth—Memantine—Alzheimer's disease	0.000196	0.00101	CcSEcCtD
Naltrexone—Asthenia—Galantamine—Alzheimer's disease	0.000196	0.00101	CcSEcCtD
Naltrexone—Anxiety—Rivastigmine—Alzheimer's disease	0.000195	0.00101	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.000195	0.00101	CcSEcCtD
Naltrexone—Confusional state—Memantine—Alzheimer's disease	0.000194	0.001	CcSEcCtD
Naltrexone—Discomfort—Rivastigmine—Alzheimer's disease	0.000194	0.001	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.000193	0.000996	CcSEcCtD
Naltrexone—Oedema—Memantine—Alzheimer's disease	0.000192	0.000993	CcSEcCtD
Naltrexone—Dry mouth—Rivastigmine—Alzheimer's disease	0.000192	0.000991	CcSEcCtD
Naltrexone—Insomnia—Donepezil—Alzheimer's disease	0.000191	0.000989	CcSEcCtD
Naltrexone—Infection—Memantine—Alzheimer's disease	0.000191	0.000986	CcSEcCtD
Naltrexone—Paraesthesia—Donepezil—Alzheimer's disease	0.00019	0.000982	CcSEcCtD
Naltrexone—Confusional state—Rivastigmine—Alzheimer's disease	0.00019	0.000979	CcSEcCtD
Naltrexone—Shock—Memantine—Alzheimer's disease	0.000189	0.000977	CcSEcCtD
Naltrexone—Dyspnoea—Donepezil—Alzheimer's disease	0.000189	0.000975	CcSEcCtD
Naltrexone—Nervous system disorder—Memantine—Alzheimer's disease	0.000188	0.000974	CcSEcCtD
Naltrexone—Somnolence—Donepezil—Alzheimer's disease	0.000188	0.000972	CcSEcCtD
Naltrexone—Oedema—Rivastigmine—Alzheimer's disease	0.000188	0.000971	CcSEcCtD
Naltrexone—Tachycardia—Memantine—Alzheimer's disease	0.000188	0.000969	CcSEcCtD
Naltrexone—Diarrhoea—Galantamine—Alzheimer's disease	0.000187	0.000965	CcSEcCtD
Naltrexone—Infection—Rivastigmine—Alzheimer's disease	0.000187	0.000965	CcSEcCtD
Naltrexone—Skin disorder—Memantine—Alzheimer's disease	0.000187	0.000964	CcSEcCtD
Naltrexone—Hyperhidrosis—Memantine—Alzheimer's disease	0.000186	0.00096	CcSEcCtD
Naltrexone—Shock—Rivastigmine—Alzheimer's disease	0.000185	0.000956	CcSEcCtD
Naltrexone—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.000184	0.000952	CcSEcCtD
Naltrexone—Decreased appetite—Donepezil—Alzheimer's disease	0.000184	0.00095	CcSEcCtD
Naltrexone—Tachycardia—Rivastigmine—Alzheimer's disease	0.000183	0.000948	CcSEcCtD
Naltrexone—Anorexia—Memantine—Alzheimer's disease	0.000183	0.000946	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.000183	0.000944	CcSEcCtD
Naltrexone—Skin disorder—Rivastigmine—Alzheimer's disease	0.000183	0.000943	CcSEcCtD
Naltrexone—Fatigue—Donepezil—Alzheimer's disease	0.000182	0.000943	CcSEcCtD
Naltrexone—Hyperhidrosis—Rivastigmine—Alzheimer's disease	0.000182	0.000939	CcSEcCtD
Naltrexone—Constipation—Donepezil—Alzheimer's disease	0.000181	0.000935	CcSEcCtD
Naltrexone—Pain—Donepezil—Alzheimer's disease	0.000181	0.000935	CcSEcCtD
Naltrexone—Dizziness—Galantamine—Alzheimer's disease	0.000181	0.000933	CcSEcCtD
Naltrexone—Anorexia—Rivastigmine—Alzheimer's disease	0.000179	0.000926	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.000175	0.000904	CcSEcCtD
Naltrexone—Feeling abnormal—Donepezil—Alzheimer's disease	0.000174	0.000901	CcSEcCtD
Naltrexone—Insomnia—Memantine—Alzheimer's disease	0.000174	0.000898	CcSEcCtD
Naltrexone—Vomiting—Galantamine—Alzheimer's disease	0.000174	0.000897	CcSEcCtD
Naltrexone—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.000173	0.000894	CcSEcCtD
Naltrexone—Paraesthesia—Memantine—Alzheimer's disease	0.000173	0.000891	CcSEcCtD
Naltrexone—Rash—Galantamine—Alzheimer's disease	0.000172	0.00089	CcSEcCtD
Naltrexone—Dermatitis—Galantamine—Alzheimer's disease	0.000172	0.000889	CcSEcCtD
Naltrexone—ABCB1—brain—Alzheimer's disease	0.000172	0.0065	CbGeAlD
Naltrexone—Dyspnoea—Memantine—Alzheimer's disease	0.000171	0.000885	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	0.000171	0.000885	CcSEcCtD
Naltrexone—Headache—Galantamine—Alzheimer's disease	0.000171	0.000884	CcSEcCtD
Naltrexone—Morphine—CYP2D6—Alzheimer's disease	0.000171	0.0419	CrCbGaD
Naltrexone—Somnolence—Memantine—Alzheimer's disease	0.000171	0.000883	CcSEcCtD
Naltrexone—Insomnia—Rivastigmine—Alzheimer's disease	0.00017	0.000878	CcSEcCtD
Naltrexone—Paraesthesia—Rivastigmine—Alzheimer's disease	0.000169	0.000872	CcSEcCtD
Naltrexone—Urticaria—Donepezil—Alzheimer's disease	0.000168	0.000869	CcSEcCtD
Naltrexone—Dyspnoea—Rivastigmine—Alzheimer's disease	0.000168	0.000866	CcSEcCtD
Naltrexone—Abdominal pain—Donepezil—Alzheimer's disease	0.000167	0.000864	CcSEcCtD
Naltrexone—Body temperature increased—Donepezil—Alzheimer's disease	0.000167	0.000864	CcSEcCtD
Naltrexone—Somnolence—Rivastigmine—Alzheimer's disease	0.000167	0.000863	CcSEcCtD
Naltrexone—Decreased appetite—Memantine—Alzheimer's disease	0.000167	0.000863	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.000166	0.000857	CcSEcCtD
Naltrexone—Fatigue—Memantine—Alzheimer's disease	0.000166	0.000856	CcSEcCtD
Naltrexone—Pain—Memantine—Alzheimer's disease	0.000164	0.000849	CcSEcCtD
Naltrexone—Constipation—Memantine—Alzheimer's disease	0.000164	0.000849	CcSEcCtD
Naltrexone—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000163	0.000844	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.000162	0.000838	CcSEcCtD
Naltrexone—Nausea—Galantamine—Alzheimer's disease	0.000162	0.000838	CcSEcCtD
Naltrexone—Fatigue—Rivastigmine—Alzheimer's disease	0.000162	0.000837	CcSEcCtD
Naltrexone—Pain—Rivastigmine—Alzheimer's disease	0.000161	0.000831	CcSEcCtD
Naltrexone—Constipation—Rivastigmine—Alzheimer's disease	0.000161	0.000831	CcSEcCtD
Naltrexone—Feeling abnormal—Memantine—Alzheimer's disease	0.000158	0.000818	CcSEcCtD
Naltrexone—Gastrointestinal pain—Memantine—Alzheimer's disease	0.000157	0.000812	CcSEcCtD
Naltrexone—Hypersensitivity—Donepezil—Alzheimer's disease	0.000156	0.000806	CcSEcCtD
Naltrexone—Feeling abnormal—Rivastigmine—Alzheimer's disease	0.000155	0.0008	CcSEcCtD
Naltrexone—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.000154	0.000794	CcSEcCtD
Naltrexone—Urticaria—Memantine—Alzheimer's disease	0.000153	0.000789	CcSEcCtD
Naltrexone—Abdominal pain—Memantine—Alzheimer's disease	0.000152	0.000785	CcSEcCtD
Naltrexone—Body temperature increased—Memantine—Alzheimer's disease	0.000152	0.000785	CcSEcCtD
Naltrexone—Asthenia—Donepezil—Alzheimer's disease	0.000152	0.000784	CcSEcCtD
Naltrexone—Pruritus—Donepezil—Alzheimer's disease	0.00015	0.000774	CcSEcCtD
Naltrexone—Urticaria—Rivastigmine—Alzheimer's disease	0.000149	0.000772	CcSEcCtD
Naltrexone—Body temperature increased—Rivastigmine—Alzheimer's disease	0.000149	0.000768	CcSEcCtD
Naltrexone—Abdominal pain—Rivastigmine—Alzheimer's disease	0.000149	0.000768	CcSEcCtD
Naltrexone—Diarrhoea—Donepezil—Alzheimer's disease	0.000145	0.000748	CcSEcCtD
Naltrexone—Hypersensitivity—Memantine—Alzheimer's disease	0.000142	0.000731	CcSEcCtD
Naltrexone—Dizziness—Donepezil—Alzheimer's disease	0.00014	0.000723	CcSEcCtD
Naltrexone—Hypersensitivity—Rivastigmine—Alzheimer's disease	0.000138	0.000716	CcSEcCtD
Naltrexone—Asthenia—Memantine—Alzheimer's disease	0.000138	0.000712	CcSEcCtD
Naltrexone—Pruritus—Memantine—Alzheimer's disease	0.000136	0.000702	CcSEcCtD
Naltrexone—Asthenia—Rivastigmine—Alzheimer's disease	0.000135	0.000697	CcSEcCtD
Naltrexone—Vomiting—Donepezil—Alzheimer's disease	0.000135	0.000695	CcSEcCtD
Naltrexone—Rash—Donepezil—Alzheimer's disease	0.000133	0.000689	CcSEcCtD
Naltrexone—Dermatitis—Donepezil—Alzheimer's disease	0.000133	0.000689	CcSEcCtD
Naltrexone—Pruritus—Rivastigmine—Alzheimer's disease	0.000133	0.000687	CcSEcCtD
Naltrexone—Headache—Donepezil—Alzheimer's disease	0.000133	0.000685	CcSEcCtD
Naltrexone—Diarrhoea—Memantine—Alzheimer's disease	0.000131	0.000679	CcSEcCtD
Naltrexone—Diarrhoea—Rivastigmine—Alzheimer's disease	0.000129	0.000665	CcSEcCtD
Naltrexone—Dizziness—Memantine—Alzheimer's disease	0.000127	0.000656	CcSEcCtD
Naltrexone—Nausea—Donepezil—Alzheimer's disease	0.000126	0.000649	CcSEcCtD
Naltrexone—Dizziness—Rivastigmine—Alzheimer's disease	0.000124	0.000642	CcSEcCtD
Naltrexone—Vomiting—Memantine—Alzheimer's disease	0.000122	0.000631	CcSEcCtD
Naltrexone—Rash—Memantine—Alzheimer's disease	0.000121	0.000626	CcSEcCtD
Naltrexone—Dermatitis—Memantine—Alzheimer's disease	0.000121	0.000625	CcSEcCtD
Naltrexone—Headache—Memantine—Alzheimer's disease	0.00012	0.000622	CcSEcCtD
Naltrexone—Vomiting—Rivastigmine—Alzheimer's disease	0.00012	0.000618	CcSEcCtD
Naltrexone—Rash—Rivastigmine—Alzheimer's disease	0.000119	0.000612	CcSEcCtD
Naltrexone—Dermatitis—Rivastigmine—Alzheimer's disease	0.000118	0.000612	CcSEcCtD
Naltrexone—Headache—Rivastigmine—Alzheimer's disease	0.000118	0.000608	CcSEcCtD
Naltrexone—Nausea—Memantine—Alzheimer's disease	0.000114	0.00059	CcSEcCtD
Naltrexone—Nausea—Rivastigmine—Alzheimer's disease	0.000112	0.000577	CcSEcCtD
Naltrexone—UGT1A1—Metabolism—GAPDH—Alzheimer's disease	2.41e-05	0.000722	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCL2—Alzheimer's disease	2.41e-05	0.000721	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CCR5—Alzheimer's disease	2.4e-05	0.000719	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PSENEN—Alzheimer's disease	2.37e-05	0.000707	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—HTR2A—Alzheimer's disease	2.35e-05	0.000703	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APH1A—Alzheimer's disease	2.33e-05	0.000697	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—A2M—Alzheimer's disease	2.33e-05	0.000697	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GAPDHS—Alzheimer's disease	2.31e-05	0.000691	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PLCB1—Alzheimer's disease	2.31e-05	0.00069	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PRKCG—Alzheimer's disease	2.3e-05	0.000689	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NPY—Alzheimer's disease	2.29e-05	0.000686	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—CP—Alzheimer's disease	2.28e-05	0.000683	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IAPP—Alzheimer's disease	2.28e-05	0.000681	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NCSTN—Alzheimer's disease	2.27e-05	0.000679	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—A2M—Alzheimer's disease	2.26e-05	0.000675	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—Alzheimer's disease	2.25e-05	0.000674	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PRKCG—Alzheimer's disease	2.22e-05	0.000665	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LRP1—Alzheimer's disease	2.21e-05	0.000662	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CRH—Alzheimer's disease	2.21e-05	0.000662	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ATP5A1—Alzheimer's disease	2.19e-05	0.000655	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PSEN2—Alzheimer's disease	2.18e-05	0.000653	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCR5—Alzheimer's disease	2.18e-05	0.000653	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—Alzheimer's disease	2.17e-05	0.000648	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GAL—Alzheimer's disease	2.16e-05	0.000647	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GFAP—Alzheimer's disease	2.16e-05	0.000647	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HTR2A—Alzheimer's disease	2.14e-05	0.000639	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—AKT1—Alzheimer's disease	2.11e-05	0.000632	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCR5—Alzheimer's disease	2.11e-05	0.00063	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NPS—Alzheimer's disease	2.1e-05	0.000627	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLD3—Alzheimer's disease	2.09e-05	0.000625	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PPP3CA—Alzheimer's disease	2.09e-05	0.000624	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—HTR2A—Alzheimer's disease	2.06e-05	0.000617	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—F2—Alzheimer's disease	2.06e-05	0.000617	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTK2B—Alzheimer's disease	2.06e-05	0.000615	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ACHE—Alzheimer's disease	2.03e-05	0.000607	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PRKCG—Alzheimer's disease	2.02e-05	0.000604	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NPY—Alzheimer's disease	2.01e-05	0.000601	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—INPP5D—Alzheimer's disease	2.01e-05	0.0006	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HSD17B10—Alzheimer's disease	2e-05	0.000599	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SST—Alzheimer's disease	2e-05	0.000598	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NTRK2—Alzheimer's disease	2e-05	0.000598	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GAB2—Alzheimer's disease	2e-05	0.000598	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IAPP—Alzheimer's disease	2e-05	0.000598	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CALM1—Alzheimer's disease	1.99e-05	0.000596	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GSK3A—Alzheimer's disease	1.98e-05	0.000593	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APP—Alzheimer's disease	1.95e-05	0.000583	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—TF—Alzheimer's disease	1.94e-05	0.000581	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CRH—Alzheimer's disease	1.94e-05	0.00058	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP46A1—Alzheimer's disease	1.93e-05	0.000577	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCR5—Alzheimer's disease	1.91e-05	0.000572	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—A2M—Alzheimer's disease	1.91e-05	0.00057	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS1—Alzheimer's disease	1.9e-05	0.000568	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ENO1—Alzheimer's disease	1.9e-05	0.000568	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—Alzheimer's disease	1.89e-05	0.000566	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PRKCG—Alzheimer's disease	1.88e-05	0.000562	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HTR2A—Alzheimer's disease	1.87e-05	0.00056	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—F2—Alzheimer's disease	1.87e-05	0.00056	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP2D6—Alzheimer's disease	1.86e-05	0.000557	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ND1—Alzheimer's disease	1.86e-05	0.000557	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PSEN2—Alzheimer's disease	1.85e-05	0.000552	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PLCB1—Alzheimer's disease	1.84e-05	0.00055	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NPS—Alzheimer's disease	1.84e-05	0.00055	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PPP3CA—Alzheimer's disease	1.83e-05	0.000547	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—F2—Alzheimer's disease	1.81e-05	0.000541	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTK2B—Alzheimer's disease	1.8e-05	0.000539	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Alzheimer's disease	1.8e-05	0.000537	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCR5—Alzheimer's disease	1.78e-05	0.000533	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—BCHE—Alzheimer's disease	1.77e-05	0.000528	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NTRK2—Alzheimer's disease	1.75e-05	0.000525	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SST—Alzheimer's disease	1.75e-05	0.000525	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GAB2—Alzheimer's disease	1.75e-05	0.000525	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CALM1—Alzheimer's disease	1.75e-05	0.000522	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—HTR2A—Alzheimer's disease	1.74e-05	0.000521	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GSK3A—Alzheimer's disease	1.74e-05	0.00052	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NGFR—Alzheimer's disease	1.72e-05	0.000513	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APP—Alzheimer's disease	1.71e-05	0.000511	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PRKCG—Alzheimer's disease	1.71e-05	0.00051	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CREB1—Alzheimer's disease	1.71e-05	0.00051	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NPY—Alzheimer's disease	1.7e-05	0.000508	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IAPP—Alzheimer's disease	1.69e-05	0.000505	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADAM10—Alzheimer's disease	1.68e-05	0.000501	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL2—Alzheimer's disease	1.67e-05	0.000499	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—Alzheimer's disease	1.67e-05	0.000499	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PLCB1—Alzheimer's disease	1.67e-05	0.000499	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—F2—Alzheimer's disease	1.64e-05	0.000491	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CRH—Alzheimer's disease	1.64e-05	0.00049	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCR5—Alzheimer's disease	1.62e-05	0.000484	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ABCA1—Alzheimer's disease	1.62e-05	0.000483	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PLCB1—Alzheimer's disease	1.61e-05	0.000482	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—S100B—Alzheimer's disease	1.59e-05	0.000474	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HTR2A—Alzheimer's disease	1.58e-05	0.000473	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NPS—Alzheimer's disease	1.55e-05	0.000465	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PPP3CA—Alzheimer's disease	1.55e-05	0.000462	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—Alzheimer's disease	1.53e-05	0.000458	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—F2—Alzheimer's disease	1.53e-05	0.000457	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTK2B—Alzheimer's disease	1.52e-05	0.000456	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF2—Alzheimer's disease	1.51e-05	0.000451	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NGFR—Alzheimer's disease	1.51e-05	0.00045	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CREB1—Alzheimer's disease	1.5e-05	0.000447	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GAB2—Alzheimer's disease	1.48e-05	0.000443	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NTRK2—Alzheimer's disease	1.48e-05	0.000443	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SST—Alzheimer's disease	1.48e-05	0.000443	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CALM1—Alzheimer's disease	1.48e-05	0.000442	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADAM10—Alzheimer's disease	1.47e-05	0.00044	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GSK3A—Alzheimer's disease	1.47e-05	0.000439	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL2—Alzheimer's disease	1.46e-05	0.000438	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1R—Alzheimer's disease	1.46e-05	0.000436	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APP—Alzheimer's disease	1.44e-05	0.000432	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—Alzheimer's disease	1.42e-05	0.000423	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LPL—Alzheimer's disease	1.4e-05	0.000418	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARGC1A—Alzheimer's disease	1.39e-05	0.000417	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—S100B—Alzheimer's disease	1.39e-05	0.000416	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—F2—Alzheimer's disease	1.39e-05	0.000415	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MEF2C—Alzheimer's disease	1.39e-05	0.000415	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HMOX1—Alzheimer's disease	1.39e-05	0.000415	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PLCB1—Alzheimer's disease	1.36e-05	0.000408	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PRKCG—Alzheimer's disease	1.36e-05	0.000407	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—HMOX1—Alzheimer's disease	1.36e-05	0.000406	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NGF—Alzheimer's disease	1.33e-05	0.000396	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF2—Alzheimer's disease	1.32e-05	0.000396	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—Alzheimer's disease	1.3e-05	0.000388	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCR5—Alzheimer's disease	1.29e-05	0.000386	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1R—Alzheimer's disease	1.28e-05	0.000383	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NGFR—Alzheimer's disease	1.27e-05	0.00038	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—LPL—Alzheimer's disease	1.27e-05	0.000379	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CREB1—Alzheimer's disease	1.26e-05	0.000378	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR2A—Alzheimer's disease	1.26e-05	0.000377	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADAM10—Alzheimer's disease	1.24e-05	0.000372	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL2—Alzheimer's disease	1.24e-05	0.00037	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LPL—Alzheimer's disease	1.23e-05	0.000367	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MEF2C—Alzheimer's disease	1.22e-05	0.000364	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Alzheimer's disease	1.21e-05	0.000363	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CHAT—Alzheimer's disease	1.2e-05	0.000359	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TPI1—Alzheimer's disease	1.2e-05	0.000359	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PRKCG—Alzheimer's disease	1.19e-05	0.000357	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CALM1—Alzheimer's disease	1.18e-05	0.000352	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—S100B—Alzheimer's disease	1.18e-05	0.000351	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LEP—Alzheimer's disease	1.17e-05	0.000351	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOE—Alzheimer's disease	1.17e-05	0.000351	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NGF—Alzheimer's disease	1.16e-05	0.000347	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CAV1—Alzheimer's disease	1.16e-05	0.000347	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MAOB—Alzheimer's disease	1.15e-05	0.000344	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—Alzheimer's disease	1.14e-05	0.000341	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR5—Alzheimer's disease	1.13e-05	0.000338	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ESR1—Alzheimer's disease	1.12e-05	0.000335	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF2—Alzheimer's disease	1.12e-05	0.000335	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GAPDH—Alzheimer's disease	1.11e-05	0.000331	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR2A—Alzheimer's disease	1.11e-05	0.000331	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—F2—Alzheimer's disease	1.11e-05	0.000331	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH1—Alzheimer's disease	1.08e-05	0.000324	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1R—Alzheimer's disease	1.08e-05	0.000323	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—A2M—Alzheimer's disease	1.07e-05	0.00032	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—Alzheimer's disease	1.07e-05	0.00032	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CALM1—Alzheimer's disease	1.07e-05	0.000319	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOE—Alzheimer's disease	1.06e-05	0.000318	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CAV1—Alzheimer's disease	1.05e-05	0.000315	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LPL—Alzheimer's disease	1.04e-05	0.00031	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CALM1—Alzheimer's disease	1.03e-05	0.000309	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LEP—Alzheimer's disease	1.03e-05	0.000308	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOE—Alzheimer's disease	1.03e-05	0.000308	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MEF2C—Alzheimer's disease	1.03e-05	0.000307	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CAV1—Alzheimer's disease	1.02e-05	0.000305	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GSK3B—Alzheimer's disease	1.02e-05	0.000304	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PRKCG—Alzheimer's disease	1.01e-05	0.000301	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CREB1—Alzheimer's disease	1.01e-05	0.000301	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—INS—Alzheimer's disease	1e-05	0.0003	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL2—Alzheimer's disease	9.86e-06	0.000295	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NGF—Alzheimer's disease	9.82e-06	0.000294	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ESR1—Alzheimer's disease	9.82e-06	0.000294	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—F2—Alzheimer's disease	9.7e-06	0.00029	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1—Alzheimer's disease	9.69e-06	0.00029	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR5—Alzheimer's disease	9.55e-06	0.000286	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH1—Alzheimer's disease	9.49e-06	0.000284	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR2A—Alzheimer's disease	9.35e-06	0.00028	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ACHE—Alzheimer's disease	9.31e-06	0.000278	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARG—Alzheimer's disease	9.26e-06	0.000277	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—INPP5D—Alzheimer's disease	9.2e-06	0.000275	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—INS—Alzheimer's disease	9.08e-06	0.000272	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—Alzheimer's disease	9.03e-06	0.00027	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GSK3B—Alzheimer's disease	8.91e-06	0.000266	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CREB1—Alzheimer's disease	8.84e-06	0.000264	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOS3—Alzheimer's disease	8.79e-06	0.000263	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—INS—Alzheimer's disease	8.79e-06	0.000263	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CALM1—Alzheimer's disease	8.72e-06	0.000261	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ENO1—Alzheimer's disease	8.72e-06	0.000261	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS1—Alzheimer's disease	8.72e-06	0.000261	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LEP—Alzheimer's disease	8.69e-06	0.00026	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOE—Alzheimer's disease	8.69e-06	0.00026	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL2—Alzheimer's disease	8.65e-06	0.000258	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CAV1—Alzheimer's disease	8.61e-06	0.000258	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2D6—Alzheimer's disease	8.55e-06	0.000256	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1—Alzheimer's disease	8.5e-06	0.000254	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ESR1—Alzheimer's disease	8.3e-06	0.000248	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—F2—Alzheimer's disease	8.2e-06	0.000245	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—BCHE—Alzheimer's disease	8.11e-06	0.000242	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH1—Alzheimer's disease	8.02e-06	0.00024	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NOS3—Alzheimer's disease	7.96e-06	0.000238	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOS3—Alzheimer's disease	7.71e-06	0.00023	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLCB1—Alzheimer's disease	7.65e-06	0.000229	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—Alzheimer's disease	7.53e-06	0.000225	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GSK3B—Alzheimer's disease	7.53e-06	0.000225	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CREB1—Alzheimer's disease	7.47e-06	0.000223	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP3—Alzheimer's disease	7.46e-06	0.000223	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—INS—Alzheimer's disease	7.43e-06	0.000222	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCA1—Alzheimer's disease	7.41e-06	0.000222	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—Alzheimer's disease	7.41e-06	0.000222	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL2—Alzheimer's disease	7.31e-06	0.000218	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—Alzheimer's disease	7.28e-06	0.000218	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1—Alzheimer's disease	7.18e-06	0.000215	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK8—Alzheimer's disease	6.86e-06	0.000205	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—Alzheimer's disease	6.84e-06	0.000204	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—Alzheimer's disease	6.6e-06	0.000197	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP3—Alzheimer's disease	6.54e-06	0.000196	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOS3—Alzheimer's disease	6.51e-06	0.000195	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—Alzheimer's disease	6.5e-06	0.000194	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARGC1A—Alzheimer's disease	6.39e-06	0.000191	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMOX1—Alzheimer's disease	6.36e-06	0.00019	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—Alzheimer's disease	6.33e-06	0.000189	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK8—Alzheimer's disease	6.01e-06	0.00018	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—Alzheimer's disease	6e-06	0.000179	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LPL—Alzheimer's disease	5.82e-06	0.000174	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFB1—Alzheimer's disease	5.81e-06	0.000174	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—Alzheimer's disease	5.58e-06	0.000167	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—Alzheimer's disease	5.55e-06	0.000166	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP3—Alzheimer's disease	5.53e-06	0.000165	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—Alzheimer's disease	5.49e-06	0.000164	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—Alzheimer's disease	5.24e-06	0.000157	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFB1—Alzheimer's disease	5.1e-06	0.000152	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK8—Alzheimer's disease	5.08e-06	0.000152	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—Alzheimer's disease	5.07e-06	0.000152	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CALM1—Alzheimer's disease	4.89e-06	0.000146	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOE—Alzheimer's disease	4.88e-06	0.000146	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CAV1—Alzheimer's disease	4.83e-06	0.000144	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—Alzheimer's disease	4.78e-06	0.000143	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—Alzheimer's disease	4.69e-06	0.00014	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—Alzheimer's disease	4.38e-06	0.000131	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFB1—Alzheimer's disease	4.31e-06	0.000129	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARG—Alzheimer's disease	4.25e-06	0.000127	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—Alzheimer's disease	4.19e-06	0.000125	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—INS—Alzheimer's disease	4.17e-06	0.000125	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—Alzheimer's disease	4.04e-06	0.000121	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—Alzheimer's disease	3.84e-06	0.000115	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—Alzheimer's disease	3.66e-06	0.000109	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NOS3—Alzheimer's disease	3.65e-06	0.000109	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—Alzheimer's disease	3.55e-06	0.000106	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—Alzheimer's disease	3.54e-06	0.000106	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—Alzheimer's disease	3.34e-06	9.99e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—Alzheimer's disease	3.24e-06	9.7e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—Alzheimer's disease	2.99e-06	8.95e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—Alzheimer's disease	1.68e-06	5.02e-05	CbGpPWpGaD
